

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10591843	
	Filing Date		2006-09-05	
	First Named Inventor	Tomoaki Hoshino et al.		
	Art Unit			
	Examiner Name			
Attorney Docket Number		KUP-12		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2001510997	JP		2001-08-07	Karobio, A. et al.		<input type="checkbox"/>
	2	63230637	JP		1988-09-27	Nikken Chemical Co. Ltd.		<input type="checkbox"/>
	3	0237189	EP		1987-09-16	Pigiet, V. et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10591843
Filing Date		2006-09-05
First Named Inventor	Tomoaki Hoshino et al.	
Art Unit		
Examiner Name		
Attorney Docket Number	KUP-12	

4	2005060408	JP		2005-03-10	Jiyunji, Y. et al.		<input type="checkbox"/>
5	9832863	WO		1996-07-30	Spyrou, G.		<input type="checkbox"/>
6	1085087	JP		1989-03-30	Jiyunji, Y. et al.		<input type="checkbox"/>
7	11147895	JP		1999-06-02	Hideki, A. et al.		<input type="checkbox"/>
8	5139982	JP		1993-06-08	Hiromi, W. et al.		<input type="checkbox"/>
9	5255218	JP		1993-10-05	Chapman, K. et al.		<input type="checkbox"/>
10	10504285	JP		1996-04-28	Bemis, G. W. et al.		<input type="checkbox"/>
11	9724339	WO		1997-07-10	Kazuyuki, O. et al.		<input type="checkbox"/>
12	11100400	JP		1999-04-13	Kakuji, T. et al.		<input type="checkbox"/>
13	11147873	JP		1999-06-02	Hideki, A. et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10591843
Filing Date	2006-09-05
First Named Inventor	Tomoaki Hoshino et al.
Art Unit	
Examiner Name	
Attorney Docket Number	KUP-12

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Ueda, S. et al., Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c1; J. Immunol, 1998 Vol. 161, No. 12 pp. 6689-6695.	<input type="checkbox"/>
	2	Farina, A.R. et al; Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion; Eur. J. Biochem 26A, 405-413; (2001).	<input type="checkbox"/>
	3	Sen, C.K.; Redox signaling and the emerging therapeutic potential of thiol and antioxidants; Biochem Pharmacol, 1998, Vol. 55, No. 11, pp 1747-1758.	<input type="checkbox"/>
	4	MacNee, W. et al.; Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease; Am. J. Respir. Crit Care Med; 1999; Vol. 160, No. 5, Pt 2; pp S58-65.	<input type="checkbox"/>
	5	Pomerantz, J.J. et al.; Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta; Proc. Natl. Acad. Sci USA; 2001; Vol. 98, No. 5; P 2871-2876.	<input type="checkbox"/>
	6	Pauwels, R.A. et al; "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLB/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary"; American Journal Respiratory Critical Care Medicine, vol.163:P.1256-1276, 2001	<input type="checkbox"/>
	7	Barnes, P.J. "Novel approaches and targets for treatment of chronic obstructive pulmonary disease"; American Journal Respiratory Critical Care Medicine; Vol.160: S72-79, 1999.	<input type="checkbox"/>
	8	Shapiro, S.S.; "Animal models for COPD"; Chest, 117: 223S-227S, 2000	<input type="checkbox"/>
	9	Peri, A. et al "Early restriction of peripheral and proximal cell lineages during formation of the lung", Proc Natl Acad Sci USA 2002 Aug 6, 99 (16): 10482-10487	<input type="checkbox"/>
	10	Stripp, B. et al., "cis-acting elements that confer lung epithelial cell expression of the CC10 gene", J Biol Chem, 1992 Jul 25; Vol. 267 (21): 14703-14712	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10591843
Filing Date	2006-09-05
First Named Inventor	Tomoaki Hoshino et al.
Art Unit	
Examiner Name	
Attorney Docket Number	KUP-12

11	Carroll, W.L. et al, "Hybridoma fusion cell lines contain an aberrant kappa transcript"; 1985. Mol Immunol, Vol. 25 No. 19, 991-995	<input type="checkbox"/>
12	Kozak, M.; "Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs"; Nucleic Acids Res. 1984 Jan 25; 12 (2): 857-72.	<input type="checkbox"/>
13	Goldman, L.A. et al; "Modifications of vectors pEF-BOS, pcDNA1 and pcDNA3 result in improved convenience and expression"; Bio Techniques 21; 1013-1015; (1996).	<input type="checkbox"/>
14	Hoshino T, et al; "Cutting edge: IL-18-transgenic mice: In Vivo evidence of a broad role for IL-18 in modulating immune function"; J Immunol 2001; 166: 7014-7018	<input type="checkbox"/>
15	Kawase Y, et al; "Exacerbated and Prolonged Allergic and Non-Allergic Inflammatory Cutaneous Reaction in Mice with targeted Interleukin-18 Expression in the Skin"; J Invest Dermatol; 121; 502-509; (2003)	<input type="checkbox"/>
16	Thornberry, N. et al.; "A Novel heterodimeric cysteine protease is required for interleukin 1b processing in monocytes" Nature 356; 768-775, 1992	<input type="checkbox"/>
17	Novick, D. et al., "Interleukin-18 Binding Protein: A Novel Modulator of the Th1 Cytokine Response"; Immunity; Vol. 10; pp 127-136; 1999	<input type="checkbox"/>
18	Kitasato, Y. et al.; "Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis"; AM J Respir Cell Mol Biol, 31: 619-625, 2004	<input type="checkbox"/>
19	Palombella, V. et al.; "Role of the proteasome and NF-kB in streptococcal cell wall-induced polyarthritis"; Proc Natl Acad Sci USA, Vol. 95 PP. 15671-15676, December 1998 Medical Sciences	<input type="checkbox"/>
20	Nakamura, H. et al., "Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS; PNAS; Vol. 98, No. 5; 2688-2693 (2001)	<input type="checkbox"/>
21	Reznikov, L. et al., "The Combination of soluble IL-18Ra and IL-18Rβ Chains Inhibits IL-18-induced IFN-γ"; Journal of Interferon and cytokine research; 22: 593-601 (2002).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10591843
Filing Date	2006-09-05
First Named Inventor	Tomoaki Hoshino et al.
Art Unit	
Examiner Name	
Attorney Docket Number	KUP-12

22	Taniguchi, M. et al.; "Establishment of the cells useful for murine interleukin-18 bioassay by introducing murine interleukin-18 receptor cDNA into human myelomonocytic KG-1 cells"; J.Immunol Methods; 217, 97-102(1998).	<input type="checkbox"/>
----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.